Abstract:
Hyper (dys) lipidemia develop because of type II diabetes mellitus or cause it.
Effort has been put into refining treatment strategies for diabetes and for the elevated lipid
levels that induce many additional co-morbidities, both major and minor. Metformin, the
most common biguanide prescribed to diabetics also has lipid lowering effects. A number
of separate remedies have been tried and tested on animals and humans to try to manage
lipid levels. However, the most popular choice to date are statin drugs that are able to
reduce circulating lipid levels up to a point and require other drugs to reduce levels
adequately. Ezetimibe has been proven effective in lowering lipid levels in type II diabetes
in a number of clinical trials and could be a useful adjunct to pitavastatin. However, very
few trials have been conducted on pitavastatin and ezetimibe efficacy on hyperlipidemia or
dyslipidemia in type II diabetes. Moreover, all of the trials produced in search results were
operated in Japan. Authors of the trials have suggested that more investigations on this
topic should be conducted to confirm their findings.
The objectives of this study were to assess the combined effects of pitavastatin and
ezetimibe on lipid levels compared to pitavastatin alone in type II diabetics on biguanide
therapy and to discover any correlations between HbA1c and lipid profile.
The study was conducted in the Internal Medicine Department of a private hospital,
NMC and the Internal Medicine Department of PNS Shifa hospital. 75 subjects of both
genders suffering from type II diabetes were enrolled into the study. The sample was
divided into three groups and their blood lipid levels were assessed before and after
administration of the therapies.
Results added to the information on treatment strategies of hyper(dys)lipidemia in
type II diabetics on biguanide therapy and effects of pitavastatin alone and combined with
ezetimibe on lipid profile. Both high dose pitavastatin and intermediate dose pitavastatin
along with ezetimibe showed significant reduction of the lipid parameters
